NASDAQ:VRDN Viridian Therapeutics Q3 2025 Earnings Report $17.46 -1.29 (-6.87%) As of 01:19 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Viridian Therapeutics EPS ResultsActual EPS-$0.34Consensus EPS -$0.82Beat/MissBeat by +$0.48One Year Ago EPSN/AViridian Therapeutics Revenue ResultsActual Revenue$70.57 millionExpected Revenue$16.21 millionBeat/MissBeat by +$54.36 millionYoY Revenue Growth+81,993.00%Viridian Therapeutics Announcement DetailsQuarterQ3 2025Date11/5/2025TimeBefore Market OpensConference Call DateWednesday, November 5, 2025Conference Call Time7:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Viridian Therapeutics Earnings HeadlinesPDUFA Decision Nears as Viridian Therapeutics (VRDN) Advances TED Pipeline and Reports Q1 ResultsMay 5 at 7:42 PM | finance.yahoo.comViridian eye disease drug surpasses expectations in late-stage trial; shares soarMay 5 at 7:42 PM | msn.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 6 at 1:00 AM | Weiss Ratings (Ad)VRDN stock records biggest single day gains in 45 months – and it’s not just due to a better-than-feared Q1 lossMay 5 at 7:42 PM | msn.comViridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye Disease TranscriptMay 5 at 6:07 PM | seekingalpha.comViridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred StockMay 5 at 4:05 PM | businesswire.comSee More Viridian Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Viridian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Viridian Therapeutics and other key companies, straight to your email. Email Address About Viridian TherapeuticsViridian Therapeutics (NASDAQ:VRDN) (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders. In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases. Both candidates are being evaluated in multiple clinical trials across North America and Europe, underscoring the company’s commitment to building a robust pipeline of precision biologics. Viridian’s research platform leverages advanced antibody engineering to enhance potency, selectivity and pharmacokinetic properties, supporting the development of differentiated therapies with the potential for best-in-class profiles. Founded in 2020 and headquartered in Boston, Massachusetts, Viridian was established by a team of experienced biotechnology entrepreneurs and scientists. The company completed its initial public offering in 2021 to secure funding for clinical development and manufacturing scale-up. Under the leadership of Chief Executive Officer Mara Aspinall and Chief Medical Officer Michael Rosenzweig, Viridian has formed strategic partnerships with contract development and manufacturing organizations to support its late-stage programs. Viridian’s global footprint extends through clinical sites and collaborative networks aimed at delivering novel treatments to patients worldwide.View Viridian Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Boarding Passes Now Being Issued for the Ultimate eVTOL ArbitrageYears in the Making, AMD’s Upside Movement Has Just BegunWestern Digital: The Storage Behemoth Skyrocketing on AI DemandOld Money, New Tech: Western Union's Crypto RebootPinterest Pins a Profit Play To Its Mood BoardJust How Big a Problem Could Amazon’s Cash Burn Rate Be?BlackBerry Rewrites Its Own Operating System Upcoming Earnings Coinbase Global (5/7/2026)Airbnb (5/7/2026)argenex (5/7/2026)Datadog (5/7/2026)Ferrovial (5/7/2026)Gilead Sciences (5/7/2026)Microchip Technology (5/7/2026)MercadoLibre (5/7/2026)Monster Beverage (5/7/2026)Canadian Natural Resources (5/7/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
